Thesis testing is a valid point, and I'd encourage all other shareholders here to go directly to identified clients/customers and gauge how they found archTIS, why they use archTIS, and query whether or not it solves a real problem for them, and what competitors came close to it.
It's up to each shareholder to do their own due diligence and build out their own thesis.
This doesn't relate to archTIS only, it's just general advice for any investment.
AR9 Price at posting:
10.5¢ Sentiment: Buy Disclosure: Held
